MYBS2 Antibody

What is MYBS2 and why are antibodies used to study it?

MYBS2 is a transcription factor that regulates sugar-responsive gene expression in plants. It competes against MYBS1 for binding to the TA box in α-Amylase (αAmy) promoters, acting as a transcriptional repressor that offsets MYBS1's transactivation activity under sugar starvation conditions . Antibodies are essential tools for studying MYBS2's expression patterns, subcellular localization, phosphorylation state, and protein-protein interactions (such as with 14-3-3 proteins).

What types of MYBS2 antibodies are available for research?

Researchers typically use several types of antibodies to study MYBS2:

• Polyclonal antibodies against full-length MYBS2

• Monoclonal antibodies targeting specific domains

• Phospho-specific antibodies that recognize MYBS2 when phosphorylated at specific residues (particularly Ser53 and Ser75)

• Antibodies recognizing MYBS2-GFP fusion proteins for co-localization studies

When selecting antibodies, researchers should prioritize those validated through genetic approaches (using knockouts) rather than only orthogonal approaches, as validation studies show genetic validations provide higher reliability .

How should I validate a MYBS2 antibody before using it in my experiments?

A comprehensive MYBS2 antibody validation should follow these steps:

This stepwise approach ensures antibody specificity and reliability for subsequent experiments .

What controls are essential when using MYBS2 antibodies in immunodetection experiments?

Essential controls include:

• Positive control: Wild-type plant tissue (preferentially from tissues with high MYBS2 expression such as root hairs, companion cells, and vascular bundles)

• Negative controls:

  • MYBS2 knockout or RNAi-suppressed plant tissue

  • Secondary antibody-only controls

  • Pre-immune serum controls (for polyclonal antibodies)

• Specificity controls:

  • Competition assays with recombinant MYBS2 protein

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

• Experimental condition controls:

  • Sugar-starved vs. sugar-provided samples to demonstrate expected localization shifts

How can I detect phosphorylation status of MYBS2 using antibodies?

MYBS2 is phosphorylated at multiple sites, most critically at Ser53 and Ser75, which regulate its interactions with 14-3-3 proteins and nuclear localization . To detect phosphorylation:

• Phospho-specific antibodies: Use antibodies specifically designed to recognize phosphorylated Ser53 or Ser75.

• Phos-Tag immunoblot assay: This specialized technique can separate phosphorylated from non-phosphorylated forms. In MYBS2 research, it revealed two phosphorylated forms with molecular masses of ~70 kDa compared to the ~56 kDa non-phosphorylated form .

• λ-phosphatase treatment: Treat protein samples with λ-phosphatase before immunoblotting to confirm phosphorylation. For MYBS2, this treatment shifts the apparent molecular weight from ~70 kDa to ~56 kDa .

• Phospho-mutant validation: Validate phospho-specific antibodies using MYBS2 constructs with Ser-to-Ala mutations (S53A and S75A) that cannot be phosphorylated or Ser-to-Asp mutations (S53D and S75D) that mimic constitutive phosphorylation .

What methods can detect nucleocytoplasmic shuttling of MYBS2 in response to sugar conditions?

MYBS2 exhibits sugar-dependent nucleocytoplasmic shuttling, localizing to the nucleus under sugar provision and to the cytoplasm under sugar starvation . To study this:

• Immunofluorescence with nuclear markers: Co-stain with DAPI or other nuclear markers to assess nuclear localization.

• Subcellular fractionation: Separate nuclear and cytoplasmic fractions biochemically, then perform western blotting with MYBS2 antibodies.

• Live cell imaging with fluorescent fusion proteins: For dynamic studies, create MYBS2-GFP/mCherry fusion proteins and track localization in real-time during sugar condition transitions.

• High-throughput microscopy with machine learning: This unbiased approach uses automated image acquisition and analysis software (like CellProfiler) to quantify nuclear versus cytoplasmic signal intensity across multiple cells .

• Co-immunoprecipitation with compartment-specific markers: Assess interactions with nuclear or cytoplasmic partners like 14-3-3 proteins .

How should I interpret conflicting results between different MYBS2 antibody detection methods?

When facing conflicting results:

• Consider antibody specificity across applications: Performance in western blot does not guarantee performance in immunofluorescence. Studies show only 39% of antibodies recommended for immunofluorescence are actually successful in this application .

• Evaluate fixation/permeabilization effects: Different protocols significantly impact antibody accessibility. For membrane-associated proteins, comparison of PFA/methanol vs. saponin protocols is essential .

• Assess phosphorylation status: MYBS2 exists in multiple phosphorylated forms, which may affect antibody recognition. Compare results with λ-phosphatase-treated samples .

• Validate using multiple approaches: According to validation studies, antibodies characterized using genetic approaches (knockouts) outperform those validated with only orthogonal approaches .

• Quantitative analysis: Use software like CellProfiler or ImageJ for unbiased quantification rather than relying on visual assessment. A direct comparison showed an R² of 0.81 between these methods .

What are the common pitfalls when studying MYBS2-14-3-3 protein interactions with antibodies?

Common pitfalls include:

• Phosphorylation-dependent binding: MYBS2 interaction with 14-3-3 proteins requires phosphorylation at Ser53. Failure to detect interactions may result from phosphatase activity in samples .

• Buffer conditions: Inappropriate buffer conditions can disrupt interactions. For MYBS2-14-3-3 interactions, maintaining phosphorylation status is critical.

• Antibody interference: Some antibodies may recognize epitopes involved in protein-protein interactions, thereby blocking detection of complexes.

• Cross-reactivity with other MYB proteins: Ensure antibodies do not cross-react with MYBS1 or other MYB family members that may also interact with 14-3-3 proteins.

• Sugar condition sensitivity: MYBS2-14-3-3 interactions are sugar-sensitive, so maintaining consistent sugar conditions during sample preparation is essential .

What are the international standards for validating MYBS2 antibodies?

According to the International Working Group for Antibody Validation (IWGAV), comprehensive validation includes :

• Orthogonal validation: Correlate antibody results with independent methods like mass spectrometry.

• Genetic validation: Test antibodies in knockout/knockdown models of MYBS2.

• Independent epitope validation: Use multiple antibodies targeting different epitopes of MYBS2.

• Expression validation: Verify signals correlate with known expression patterns (e.g., MYBS2 is preferentially expressed in root hairs, companion cells, and vascular bundles) .

• Signaling response validation: For MYBS2, verify appropriate sugar-responsive localization changes.

How can I quantitatively assess MYBS2 antibody performance across different applications?

Quantitative assessment should include:

• Signal-to-noise ratio calculation: Measure specific signal against background across a dilution series.

• Sensitivity testing: Determine lower limits of detection using recombinant protein standards.

• High-throughput microscopy with machine learning: Use automated image acquisition and CellProfiler analysis for unbiased quantification of immunofluorescence signals .

• Reproducibility assessment: Test antibody performance across different lots, operators, and staining methods (manual vs. automated) .

• Cross-application performance: Most antibodies perform inconsistently across applications. Only 23% of antibodies work in all three common applications (western blot, immunoprecipitation, and immunofluorescence) .